Compare McCormick & Company, Incorporated (MKC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Regeneron Pharmaceuticals Inc — how do they compare? McCormick & Company, Incorporated trades at $51.5 (market cap $13.96B), while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.7%). Which is the better fit depends on your goals.
| MKC | REGN | |
|---|---|---|
Market Cap | $13.96B | $83.43B |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $852.03 |
52-Week Low | $45.60 | $555.51 |
Enterprise Value | $18.57B | $78.14B |
Dividend Yield | 3.7% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a low P/E of 8.64, robust 21.91% net margin, and consistent revenue growth to $6.84B in 2025. Recent Q1 2026 earnings beat expectations, while analyst consensus is mixed with 36.67% buy ratings. The pending Unilever merger and upcoming Q3 2026 earnings on October 1, 2026, are key catalysts.
MKC presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term pressure. The Unilever deal integration and margin expansion potential support long-term growth, but execution risks and competitive pressures remain concerns. Current price sits near the analyst low target of $52.00, offering limited downside protection.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
